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# 
Introduction 
Many  researchers have worked on  observational stud- 
ies on mother to child transmission o f  HIV infection 
throughout the world since the mid-1980s [l]. Among 
the practical problems faced in these studies were dif- 
ficulties with the definitions used to calculate the rate 
oftransmission of HIV from mother to child [2]. In 
1992, a workshop was held in Ghent, Belgium, to ad- 
dress methodological issues in estimating these rates and 
a standardized methodology was proposed [3].  
There is increasing pressure to start trials to evaluate 
methods aimed at reducing mother to child transmission 
of HIV infection in developing countries, particularly 
since the recent publication o f  the results o f  the first 
zidovudine trial carried out in the United States and 
France [4,5]. In order to avoid methodological problems 
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such as those fäced when comparing transmission rates 
&om different observational studies, it is important to 
consider the comparability of the design, implementa- 
tion, analysis and reporting of results of intervention tri- 
als. 
Two workshops on these methodological issues were 
held in Ghent in September 3-5 1993 and December 
2 4  1994 under the auspices of the European Commu- 
nity AIDS Task Force, in collaboration with the Global 
Programme”:ón AIDS of the World Health Organiza- 
tion (WHO). The objectives were (1) to compare the 
rates and fäctors associated with transmission drawn from 
available cohort studies using the Ghent 1992 method- 
ology; (2) to discuss various interventions that aim to 
reduce mother to child transmission of HIV infection; 
(3) to discuss methodological issues in the design and 
conduct of intervention trials; and (4) to provide guide- 
lines for groups that might consider conducting these 
trials, particularly in developing countries. 
I 
Methods 
Twenty-two teams of investigators were asked to esti- 
mate rates of mother to child transmission of HIV in- 
fection using the Ghent 1992 methodology. In brief, this 
methodology consisted of a system of classifjring children 
born to HIV-1-infected mothers according to the child’s 
probable HIV infection status during the first 15 months 
of life [3]. The transmission rate can be calculated di- 
rectIy by applying this classification to cohorts of chil- 
dren born to HIV-seropositive mothers when sufficient 
follow-up data have been obtained to determine the 
child’s infection status. The HIV transmission rate can 
also be calculated indirectly according to the persistence 
of antibodies in a cohort of 15-month-old children born 
to HIV-seropositive mothers, together with an estimate 
of HIV-associated mortality [3]. 
, 
The International Working Group compared estimates 
of mother to child rates of transmission of HIV infec- 
tion calculated using the Ghent 1992 methodology, and 
reviewed the fsctors associated with transmission. Con- 
sensus definitions of paediatric HIV infection for use as 
endpoints in future intervention trials were developed. 
Potential interventions for reducing mother to child HIV 
transmission in the context of developing countries were 
discussed. Recommendations were made for the design 
and conduct of trials, in particular for the formulation of 
hypotheses and objectives, sample size calculation, multi- 
centre design, definition of target population, inclusion 
and exclusion criteria, use of placebo, follow-up, def- 
inition of endpoints, statistical analysis, data and safety 
monitoring board, ethical issues and the possible impact 
of trial results on public health policy. 
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Comparison cif estimates of mother to 
child transmission rates of HIV-1 and 
assessment of factors associated with 
transmission 
Rates of vertical transmission 
Data fiom 13 observational studies have been presented 
elsewhere [6]. Overall, most studies from Africa and 
Haiti have reported vertical HIV transmission rates of 
25-30%, regardless of the method of calculation. Pre- 
liminary results from Thailand are in accord with these 
figures [7]. 
Late seroconversion due to postnatal transmission of HIV 
has been reported, probably related to breast-feeding 
[8-111. This phenomenon needs further investigation, 
possibly through an international registry, but is a po- 
tential problem for the interpretation of results of ver- 
tical transmission studies. The following definition was 
proposed. A child born to an HIV-positive woman is a 
late seroconverter if he/she has been antibody-negative 
at any time between nine and 15 months of age only 
to become antibody-positive again at 15 months of age 
or older. If these cases are fiequent and such children 
are classified as infected, estimates of vertical transmission 
rates become unusually high with the direct method. 
Factors associated with transmission 
Advanced maternal HIV disease and its markers, includ- 
ing a low CD4+ lymphocyte count, are the most con- 
sistent factors so far identified in mother to child HIV 
transmission [1,12,13]. Transmission through breast- 
feeding is now beyond doubt [14] but standardization 
between studies is needed. 
Factors to be considered in the design of intervention 
trials include maternal age, syphilis, p24 antigenaemia, 
viral load, CD4+ lymphocyte count, clinical AIDS, ges- 
tational age, mode of delivery [15], length and compli- 
cations of labour, therapy before, during pregnancy and 
around the time of delivery and mode of breast-feed- 
ing. Factors useful for a better understanding of mother 
to child transmission of HIV include chorioanmionitis 
[16], viral characteristics, pregnancy complications, sex- 
ual partners during pregnancy and primary HIV infec- 
tion during pregnancy. For these latter factors, further 
research is needed. 
Timing of transmission: early diagnosis 
and definition of paediatric HIV infection 
Early diagnosis of HIV infection in infants 
The early diagnosis of HIV infection in infants is usually 
based on viral culture, polymerase chain reaction, detec- 
tion of anti-HIV immunoglobulin (1g)A (after elimina- 
tion of specific IgG), detection of p24 antigen (after dis- 
sociation of immune complexes) and in vitro production 
- _ _ ~  I 
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of anti-HIV antibodies [17]. After anti-HIV IgG, poly- 
merase chain reaction DNA is by far the most widely 
used diagnostic test in studies carried out in developing 
countries [7,18,19]. 
The sensitivity of the polymerase chain reaction tech- 
nique has been estimated at 30-50% during the first 
week of life, 70-90% at 1-2 months of age and >95% 
after 3 months of age; it may be even higher than this in 
non-breast-feeding populations [17]. However, the tech- 
niques used are not standardized, there is no common 
quality control programme, few results are available from 
prospective cohort studies in developing countries and 
the detection rates in the neonatal period are low, either 
of intrapartum and/or early postnatal transmission. The 
value of cord blood specimens remains questionable at 
the present time. Capillary blood samples collected and 
stored on filter paper may be particularly useful in studies 
in developing countries. 
It is important to include viral culture assessments at 
various follow-up points in intervention trials whenever 
possible. Data on IgA have also been published [20], but 
this technique is likely to be helpful only at 6 months 
of age or over because of its low sensitivity before this 
age. Detection of p24 antigenaemia is helped by acid 
dissociation or heat denaturation. With the latter modi- 
fication, the sensitivity of this technique may equal that 
of polymerase chain reaction [21], but its use for samples 
collected during the neonatal period needs to be assessed 
on a large scale in developing countries. More generally, 
a quality control programme of early diagnostic tech- 
niques should be implemented in the context of cohort 
studies and intervention trials on mother to child HIV 
transmission in developing countries. 
Definitions of paediatric HIV infection 
Early case definitions need to be developed for both un- 
infected and infected children born to HIV-seropositive 
mothers, in relation to the timing of transmission. It is 
n because the sensitivity of the method is low or because 
- 
. 
r not clear at present exactly when vertical HIV transmis- .- sion occurs between conception and delivery or through 
breast-feeding [l]. Transmission at a given point of time 
is not necessarily related to a single mechanism. 
The relative importance of the different times of trans- 
mission is difficult to address, but increasing indirect ev- 
idence suggests the predominance of late transmission. 
The French Collaborative Study Group estimated that 
in a non-breast-fed population, 35% of the infants are 
infected late in utero and the remaining 65% during de- 
livery [22]. In an exclusively breast-fed cohort in Kigali, 
Rwanda, the polymerase chain reaction positive rate was 
30% on cord blood and 81% at 3 months. Thus, in these 
African children born to HIV-l-infected mothers, the 
estimated transmission rate in the late postnatal period is 
5%, and in the intrapartum plus postnatal periods, 18% 
[18]. Understanding the timing of transmission is partic- 
ularly important for the design of intervention trials and 
deserves further investigation. 
While the Ghent 1992 classification of HIV infection 
used to calculate the rate of transmission by’ the direct 
method is not suitable for studying the timing of trans- 
mission, it does provide a reliable estimate of the over- 
all rate of transmission up to the age of 15-18 months 
and it should be used for comparisons between groups 
and studies. Detailed reporting of losses to follow-up 
and death is necessary for a valid estimate. A working 
hypothesis of the relative importance of each period of 
transmission has been proposed by the Pediatric Virology 
Committee of the AIDS Clinical Trials Group for non- 
breast-fed populations [23]. However, it is difficult to 
measure intra-uterine transmission in breast-fed children. 
In utero and intrapartum transmission are also difficult to 
differentiate with current methods. 
According to the general definition of vertically acquired 
HIV infection proposed by the International Working 
Group in 1993, a child born to a mother known to be 
HIV-infected is considered to be infected if (1) HIV IgG 
antibodies persist beyond 15 months of age; (2) a t  any 
age, AIDS is diagnosed or the child dies of HIV-related 
death; or (3) at any age, a positive viral culture or poly- 
merase chain reaction is obtained for the first time and 
at least one subsequent sample is also positive. 
Polymerase chain reaction and viral culture are consid- 
ered to be the standard techniques for early case defini- 
tions. These methods should be applied to three consec- 
utive samples collected between birth and 6 months of 
age, yielding 27 possible combinations of results. Table 
1 shows the consensus reached by the Working Group 
on the HIV infection status of the child for each of these 
combinations. 
Two levels of definition of early paediatric HIV infec- 
tion, confirmed and probable, are generally considered. 
In practice, in developing countries, the second and third 
samples for polymerase chain reaction testing are usually 
collected at the time diptheria-tetanus-pertussis vaccine 
is given: 45 days for the first dose and 105 days for the 
third one. Additional samples should also be collected for 
polymerase chain reaction testing during any hospitaliza- 
tion in the first 6 months of life. This schedule allows the 
following Ghent 1993 early case definitions applied on 
three consecutive blood samples: (1) in utero transmission 
if the first positive result is obtained within 1 or 2 days of 
life (a cord blood sample provides no interpretable infor- 
mation); (2) irz utero plus intrapartum transmission if the 
first positive result is obtained between 30 and 60 days 
of life; (3) intrapartum plus early postnatal transmission 
if the first positive result is obtained between 90 and 180 
days oflife. The Ghent 1993 early case definitions are not 
an alternative to the Ghent 1992 definitions for children 
aged 15 or 18 months but are complementary methods 
for measuring endpoints in intervention trials. 
Other pieces of information may also be useful for an 
early diagnosis (Table 1). These techniques include p24 
antigenaemia (at 23 months of age), anti-HIV IgA (at 
26 months ofage) or polymerase chain reaction RNA. If 
the only two positive results are obtained from the same 
i 
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Table 1. HIV infection status according to virology results from polymerase chain reaction (PCR), viral culture and p24 antigen measured in 
b l 4  specimens at birth and after 6 weeks and 3 months of life in children. born to HIV-seropositive mothers. At any age, clinical AIDS or 
HIV-related death is taken as an indication that a child is infected. From the international Working Group on Mother to Child Transmission of 
HIV, Chent, Belgium, 1993-1 994. 
Birth sample 6-week 3-month HIV status 3-month HIV status 
(1-2 days), sample, PCR sample, PCR at 3 months sample, at 3 months by 
no cord blood sample (30-60 days) (90-1 80 days) by PCR p24 antigen PCR and p24 antigen 
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Wait 
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Infected, confirmed* 
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Wait 
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Wait 
Wait 
Wait 
Infected, confirmed* 
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infected, confirmed* 
Wait 
Wait 
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Wait 
NA, not available. Cutoff point for p24 antigen not yet defined. Wait refers to PCR and/or p24 antigen and/or immunoglobulin A results at 6 
months. *Another sampie from the same child needed to exclude the possibility of labelling errors. 
sample with two different techniques, another sample 
from the same child might be needed to exclude the 
possibility of labelling errors (Table 1). Clinical criteria 
such as clinical AIDS and HIV-related deaths can also be 
used as additional criteria a t  any point in time, using the 
Ghent '1992 methodology [3]. 
Early case definitions should be developed a priori in 
intervention trials. They should be intervention-specific 
in order to take account of the mechanism(s) of trans- 
mission amenable to a given intervention and the pos- 
sible effect of the intervention itself on the timing of 
the acquisition of paediatric HIV infection. The timing 
of the transmission can be modified by an intervention, 
for example, antiretroviral drugs or passive immunization 
can delay the transnlission. Thus, the sensitivity of the 
tests used can also be modified, and late samples collected 
between 6 and 15 months of age are necessary; these 
' 
should be tested with the same laboratory techniques as 
those used in the early case definitions. 
Potential interventions to reduce 
mother to child transmission of HIV in 
developing countries 
In 1992-1994, interventions to reduce mother to child 
HIV transmission were specifically discussed at sev- 
eral international meetings and reviews were published 
[24-261. These interventions must take the timing of 
transmission into account, i.e. in utero, intrapartum or 
postnatal, but other considerations such as availability, 
cost, public health relevance, advantages and disadvan- 
tages of each method may be important too. Limiting 
factors in the assessment ofthe effectiveness nf interven- 
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tions to reduce vertical HIV transmission include (1) the 
results of the first zidovudine trial [4], a reference for 
fùture trials, (2) the limited numbers of HIV-infected 
women in industrialized countries and (3) the worldwide 
scarcity of funds and fàcilities. There is therefore a need 
to set priorities and a great need for coordination of trials 
in this field. 
The following interventions to reduce mother to child 
HIV transmission have been proposed alternatives to 
breast-feeding, caesarean section delivery, vaginal dis- 
infection, antiretroviral drugs including zidovudine and 
non-nucleoside reverse transcriptase inhibitors such as 
nevirapine, immunological interventions, either passive 
immunoprophylaxis or active immunization, and com- 
binations of interventions. Table 2 summarizes the trials 
to be carried out in developing countries and discussed 
during the 1993 and 1994 Ghent workshops. 
Table 2. Intervention trials to reduce mother to chiid transmission of 
HIV in developing countries as at December 1994. 
recommended by WHO [3l]. There is also a need for 
more information on the effect of zidovudine on the 
maternal viral load. 
A strategy of combination of interventions, such as vagi- 
nal disinfection and non-nucleoside reverse transcriptase 
inhibitors or passive and active immunization, based on 
the hepatitis B model [32], can be justified, since the 
accessible populations are limited and the interventions 
could have additive or synergistic actions. However, trials 
to evaluate these combinations will be statistically com- 
plex and none have so fir been proposed. Other inter- 
ventions such as vitamin A supplementation may also be 
evaluated for developing countries [33], based on recent 
results from qbservational studies [34]. 
Guidelines for intervention trials to 
reduce mother to child transmission of 
HIV infection 
Type of intervention Country 
Alternative to breast- Kenya (trial under way) 
South Africa (trial under way) 
Caesarean section No plan (European trials may include some 
selected centres in developing countries) 
Vaginal disinfection Burkina Faso and Côte d’Ivoire (tolerance 
study of benzalkonium chloride under way) 
Kenya (trial of chlorhexidine planned) 
Malawi (trial of chlorhexidine under way) 
South Africa (tolerance study of chlorhexidine 
Burkina Faso and Côte d‘Ivoire (tolerance 
(zidovudine) study under way) 
Côte d’Ivoire (trial planned) 
Haiti (trial planned) 
South Africa, Tanzania and Uganda 
Thailand (trials planned) 
Brazil (considered*) 
Passive immuno- Haiti (trial planned) 
Active immunization N o  plan 
Vitamin A 
Combination of N o  plan 
*Other antiretrovirals apart from zidovudine are also considered but 
none are yet available for inclusion in trials of this kind. 
feeding 
and povidone iodine planned) 
Antiretroviral drug 
(multicentre trial planned*) 
prophylaxis Uganda (trial under way) 
Malawi, South Africa and Tanzania 
supplements (considered) 
interventions 
The first phase III, randomized, placebo-controlled trial 
of zidovudine with a three-step intervention in previ- 
ously untreated women has shown an important reduc- 
tion in the rate of transmission, íÎom 25.5 to 8.3% [4] 
and recommendations have been issued for the use of 
zidovudine in pregnant women in some industrialized 
countries [27,28]. The usefulness of this drug in devel- 
oping countries is not yet clear [5,29,30] but several trials 
are already planned (Table 2), generally with simplified, 
shorter and standardized regimens of administration, as 
When attempting to evaluate an intervention to reduce 
mother to child transmission of HIV infection in a given 
population, the following criteria should be discussed 
[24]: the rationale of the intervention (putative mech- 
anism of action), the potential advantages and disad- 
vantages, particularly in terms of safety, availability, the 
cost of the trial and the public health strategy of im- 
plementation if the intervention proves effective. Several 
problems are expected in the choice of intervention and 
in the design, conduct and interpretation of trial results 
in developing countries. In particular, (1) many inter- 
ventions will be evaluated in breast-fed populations; (2) 
interventions that have to be applied early in pregnancy 
are unlikely to be realistic in most populations; and (3) 
collaboration is needed to make the best use of limited 
cohorts. 
Before implementing a preventive intervention in a pop- 
ulation, the following questions should be answered: 
What is its efficacy? What is its toxicity? What are the 
optimal conditions for use? What does it cost? Phase III 
studies in the classical comparative trial design E351 allow 
measurements of efficacy. Indeed, to generate substantial 
valid evidence, with adequate and well controlled inves- 
tigation, a comparative study is needed. The fundamental 
principle involved in a comparison of treatment groups 
in a clinical trial is that groups must be alike in all im- 
portant aspects and only differ in the treatment that each 
group receives. This is the main reason for random allo- 
cation to groups, which is the most statistically powerful 
way of achieving comparability. 
Explanatory and pragmatic approaches in 
clinical trials 
Many trials lead either to no conclusion or to con- 
clusions which are not followed by action. There are 
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several reasons for this, but the main one is usually an 
inadequately formulated primary problem with confu- 
sion between two types of objective: either to increase 
knowledge or to promote action, i.e. evaluating either 
the activity of a treatment or the efficacy of a policy. 
Thus, the sentence 'comparison of two treatments A 
and B' is ambiguous and can be taken to indicate either 
a scientific inquiry, the explanatory approach, or to a 
decision-making process, the pragmatic approach (Table 
3) [36]. Evaluating the efficacy of a new antiretroviral 
drug to reauce mother to child transmission of HIV 
infection is clearly a scientific question that requires a de- 
sign close td a laboratory experiment in a selected pop- 
ulation. In contrast, answering the question of whether 
vaginal disinfection should be recommended in develop- 
ing countries requires a different approach, in which the 
representativeness of the study groups is of paramount 
importance;. and judgement criteria other than the trans- 
mission rate, such as the clinical and biological tolerance, 
are also important in order to evaluate the cost :benefit 
ratio of this intervention. Intention-to-treat analysis, a 
method that ignores treatment modifications, is generally 
recomnfended fÏom a methodological standpoint and is 
the natural approach for a pragmatic trial. For an ex- 
planatory trial, it is essential to minimize loss to follow- 
up and improve compliance [37]. 
Table 3. Possible approaches in clinical trials to evaluate interven- 
tions that aim to reduce mother to child transmission of HIV. 
Approach Explanatory Pragmatic 
Treatments Equal conditions Optimum conditions 
Criteria One (or few) Many (efficiency, cost, etc.) 
Comparison Statistical testing Decision-making 
Patients Selected group Representative sample 
Sample size and its reduction 
The efficacy of an intervention against mother to child 
HIV transmission is based on a reduction in the trans- 
mission rate in the study population. In order to establish 
a significant difference with confidence, in a trial com- 
paring no intervention versus any intervention, several 
hundreds of mothedchild pairs must be enrolled into a 
study (Table 4) [38]. Multicentre trials or joint studies 
in developed and developing countries are needed to 
achieve this and they are particularly suitable for explana- 
tory trials. Several other advantages accrue from this or- 
ganization, such as generalizability and credibility of the 
results. However, the organization of multicentre trials 
poses logistical problems. 
Table 4. Power (probability of getting a statistically significant dif- 
ference) for a two-arm trial comparing no intervention (assumed 
transmission rate of 30%) against an intervention of varying effec- 
tiveness. 
n 
(each 
Reduction in mother to child HIV transmission to: 
group) 25% 20% 15% 1 0% 5% 
100 12 38 73 95 99 
200 20 64 95 1 O0 1 O0 
300 28 81 99 1 O0 1 O0 
400 36 91 1 O0 1 O0 1 O0 
500 43 93 1 O0 1 O0 1 O0 
1000 71 1 O0 100 - 100 1 O0 
*Power against two-tailed significance a type 1 error, 0.05. 
Factorial designs 
Combining different types of interventions may be 
worthwhile, especially if their mode and timing of effect 
may be complementary. Statistically, the most satisfactory 
design to evaluate interventions, separately and overall, is 
the factorial design. However, factorial trials lead to sta- 
tistical complexity and may require difficult negotiations 
if several manufacturers are involved. 
Judgement criteria 
The main criterion in evaluating the efficacy of an inter- 
vention to reduce mother to child transmission of HIV 
infection remains the overall transmission rate measured 
when the child is 215 months of age, depending how 
long breast-feeding is continued. However, it is not cur- 
rently possible to measure accurate and precise rates 
for each potential transmission period or mechanism of 
transmission with early case definitions. Thus, the reduc- 
tion achieved by any intervention at one time may be 
hidden by increased transmission afterwards as the sample 
at risk will be increased. It i s  particularly important to 
publish any negative trial results, and also results from the 
long-term follow-up of women and children exposed to 
interventions to reduce mother to child HIV infection, 
especially with antiretroviral agents [39]. 
Ethical issues 
General guidelines, such as those of the Council for In- 
ternational Organizations of Medical Sciences (CIOMS) 
[40], answer the basic ethical questions that arise in eval- 
uating interventions to reduce mother to child trans- 
mission of HIV Any intervention trial should be rele- 
vant to the population where the study takes place. Tri- 
als in developing countries should try to strengthen the 
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national research capacity in shared responsibility with 
donor, agencies. An ethical review within the country, 
different fiom a scientific peer review, is necessary to as- 
sess the suitability of the trial for a particular population. 
The cost of the study, the cost of the drug and the cost 
of the infrastructure needed to deliver the intervention 
once efficacy has been established are important param- 
eters in the cost-benefit analysis. Results of the trials 
should be made available to the population. 
The most important transcultural problems to be solved 
in the design and conduct of these trials occur in the 
following areas: counselling and support of the women 
enrolled, avoidance of stigmatization, informed consent, 
particularly for randomization and the use of placebo, 
confidentiality and incentives to improve compliance 
without coercion [37]. Double-blind placebo-controlled 
trials offer the best option for a rapid and scientifi- 
cally valid assessment of antiretroviral drugs in reducing 
mother to child transmission of HIV [31]. 
In a l l  trials, it is necessary to create an independent Data 
and Safety Monitoring Board. Investigators should hold 
regular msetings with the funding agencies and particu- 
lar attention should be paid to avoiding individual con- 
flicts of interest. The steering committee for each in- 
tervention trial should include national decision-mak- 
ers fiom the country where the trial takes place and 
representatives of the funding agencies. In any case, a 
long-term follow-up of women and children should be 
planned, as for trials in industrialized countries [38]. 
: 
Conclusions and perspectives 
The Ghent International Working Group formulated in- 
ternational standards for the development, implementa- 
tion and analysis of intervention trials to reduce mother 
to child transmission of HIV in developing countries. 
The optimum intervention for use in developing coun- 
tries should be simple to apply, require few antenatal vis- 
its and little active participation by the pregnant women, 
be of relatively low cost and, ideally, should not require 
HIV antibody testing. 
The development of guidelines for intervention trials is 
a continuous process and should cover all  aspects of pro- 
tocols in this field in detail. In these trials, there is a need 
for a multicentre approach and complementary protocols 
between teams. International coordination is necessary 
in order to share the information fiom ongoing and 
planned trials. This has implications for organizations like 
the Global Programme on AIDS (WHO) or the Euro- 
pean Communities AIDS Task Force which could make 
a major contribution to the success of intervention tri- 
als in supporting the coordination, the trials themselves 
and the exchange and distribution of information. Af- 
fordable, sustainable and appropriate interventions with 
proven efficacy are urgently needed to decrease the bur- 
den of mother to child HIV transmission in developing 
countries. 
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